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INTRODUCTION
Studies conducted in the 1960s conﬁrmed that transfu-
sion of platelets could signiﬁcantly decrease the incidence of
fatal hemorrhage in patients with acute leukemia [1-3]. Sub-
sequently, platelet transfusions have become routine for
both prophylaxis and treatment of clinical bleeding. In a
recent hospital survey, 70% of United States centers
reported using platelet transfusion primarily for bleeding
prophylaxis [4]. In 1962, Gaydos et al. observed that gross
hemorrhage rarely occurred in patients with platelet counts
above 20 × 109/L, even in the presence of widespread aspirin
use [1]. Although a platelet count that correlated with bleed-
ing in all patients was not identiﬁed, 20 × 109/L has become
the “trigger” value for prophylactic platelet transfusions. A
1992 survey indicated that 80% of hospitals used a trigger
value at or below 20 × 109/L [5]. In 1991, Gmur et al.
reported that in patients without bleeding the threshold for
prophylactic platelet transfusion could be safely reduced to
5 × 109/L. In patients with mild bleeding manifestations, a
trigger value of 10 × 109/L was shown to be safe [6]. Lower
transfusion thresholds may decrease donor exposure and
lead to substantial health care savings. Recent editorials have
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ABSTRACT
An optimal platelet-count threshold for prophylactic platelet transfusion in hematopoietic stem cell transplant
(HSCT) recipients has yet to be determined. Between July 1997 and December 1999, we performed the first
prospective randomized clinical trial addressing this issue in 159 HSCT recipients who received a prophylactic
platelet transfusion when the morning platelet count fell below a 10,000/µL (10K) or 20,000/µL (20K) threshold.
Subsequent prophylactic transfusions were administered according to a predetermined algorithm. The number of
prophylactic and therapeutic transfusions and the incidence of minor and major bleeding were compared between
the 2 groups. The groups were matched according to patient and transplantation characteristics. There were no
significant differences in bleeding incidence or severity. Fourteen percent of patients in the 10K arm compared to
17% in the 20K arm had major bleeding events. Only 3 central nervous system bleeds occurred, 2 in the 10K group
and 1 in the 20K group. No deaths were attributed to bleeding. An average of 11.4 days of bleeding occurred in both
groups. An average of 10.4 platelet transfusions per patient were administered in the 10K group compared to 10.2
in the 20K group (P = .94). More transfusions were given above the assigned transfusion threshold in the 10K group
than in the 20K group (4.3/patient versus 1.9/patient, respectively, P = .05). Safety measures incorporated into our
study may have precluded demonstration of significant differences in platelet use between the groups. In conclu-
sion, a platelet transfusion trigger of 10K was found to be safe; however, a decrease in platelet use was not achieved
because of safety measures incorporated into our study design.
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called for a wider acceptance of a prophylactic platelet trans-
fusion trigger of 10 × 109/L [7-9]. A recent consensus con-
ference concluded that for patients without an increased risk
of bleeding, a threshold value of 10 × 109/L for prophylactic
platelet transfusion was as safe as higher values [10].
Since 1996, 3 prospective randomized studies have evalu-
ated the safety of a lower prophylactic platelet transfusion
threshold in patients with acute leukemia undergoing induc-
tion or consolidation chemotherapy [11-15]. Heckman and
colleagues concluded that a 10 × 109/L transfusion threshold
could decrease platelet use by 4 transfusions per patient with-
out increasing red cell requirements or clinical bleeding [11].
Results of a multicenter trial by Rebulla et al. showed no
signiﬁcant differences in bleeding incidence, number of hos-
pital days, or survival rate in patients with a trigger value of
10 × 109/L compared to patients with a trigger value of 20 ×
109/L. Patients randomized to the 10 × 109/L trigger received
21% fewer platelet transfusions [12]. In 1998 Wandt and col-
leagues reported that patients receiving platelet transfusions
at a threshold of 10 × 109/L had a one-third cost reduction
for platelet transfusions without signiﬁcant differences in red
blood cell transfusion requirements or clinical bleeding [13].
To date, only one retrospective study has been published
evaluating a stringent platelet transfusion policy in bone
marrow transplant (BMT) recipients [14]. In a case-control
historical cohort study, Gil-Fernandez and colleagues
reported a signiﬁcant decrease in platelet use for patients at
a transfusion trigger lowered to 10 × 109/L compared to his-
torical control patients. No signiﬁcant difference in hemor-
rhage incidence was noted. No prospective randomized
studies have been reported in a BMT population.
BMT patients have an increased incidence of sepsis, dis-
seminated intravascular coagulation (DIC), veno-occlusive
disease (VOD), graft-versus-host disease (GVHD), and infec-
tion. These complications have been associated with both
increased bleeding risk and platelet refractoriness [16-21].
Moreover, patients who suffer bleeding after bone marrow
transplantation have lower survival rates [22].
Because the appropriate platelet transfusion trigger
threshold in BMT recipients remains uncertain, we per-
formed a randomized trial investigating 10 × 109/L versus
20 × 109/L prophylactic transfusion thresholds in BMT
patients to compare transfusion requirements and the inci-
dence of bleeding and adverse reactions.
METHODS
Patients and Methods
Between July 1997 and December 1999, patients older
than 2 years who underwent an allogeneic, matched unre-
lated donor (MUD), syngeneic, or autologous BMT were
included in our study. Patients with any of the following
indications were ineligible for the study: known bleeding
disorder or coagulopathy, concurrent need for anticoagula-
tion, history of acute hemorrhage within 1 week of enroll-
ment or within 1 week of a fall in the platelet count to below
50 × 109/L, history of prior bladder irradiation if the use of
cyclophosphamide was planned, or platelet alloimmuniza-
tion. Written informed consent was obtained from all
patients or their legal guardians. Patients were cared for in
individual rooms with laminar airflow and treated with
established conditioning regimens based on disease
processes, performance status, and prior treatment.
Study Design
On enrollment, patients were randomized into 2 groups
to receive prophylactic platelet transfusions if their morning
platelet counts fell below 20 × 109/L (20K trigger group) ver-
sus 10 × 109/L (10K trigger group). In the 10K trigger group,
if the morning platelet count ranged between 10 to 15 ×
109/L, a platelet count was checked 12 hours later and platelet
transfusion was given if the count fell below 10 × 109/L. An
automated platelet count was checked each morning in the
Shands Hospital hematology laboratory using a Coulter
GenS Hematology Analyzer (Beckman Coulter, Miami, FL).
Platelet counts continued to be monitored for 60 days in
patients receiving an autologous transplant or 100 days in
those receiving an allogeneic or MUD transplant. Platelet
counts were conﬁrmed by a manual slide review when values
fell below 50 × 109/L. A posttransfusion platelet count was
obtained 30 to 90 minutes after each transfusion. If the
platelet transfusion threshold was attained after transfusion,
then no further routine platelet transfusions were prescribed
that day. If the posttransfusion platelet count did not reach
the platelet trigger value, then action proceeded based on a
predetermined algorithm (Figure).
Several safety measures were incorporated into the pro-
tocol, as in earlier studies. The presence of an acute bleed-
ing event (therapeutic indication), recent major or minor
bleeding, planned procedures such as central line placement
or biopsies, or worsening of a patient’s clinical condition
(prophylactic indications) were reasons for the transfusion
of platelets at levels above the assigned trigger value. After
resolution of each acute event, the trigger threshold was
returned to its initial value.
All patients received single-donor apheresis platelet
products, when available; otherwise, pooled random-donor
platelets were administered. ABO-compatible single-donor
apheresis platelets were used when available; ABO incom-
patible platelets were volume reduced. All platelet products
were leukocyte depleted and irradiated. The dose of
platelets administered in adults and children with an ideal
body weight ≥50 kg was 1 unit of apheresis platelet concen-
trates. In children with an ideal body weight <50 kg, the
dose of single-donor apheresis platelets was 0.5 units/m2.
When pooled random-donor platelets were administered,
the dose was 1 unit/10 kg (6-unit minimum, 10-unit maxi-
mum). In children with an ideal body weight <50 kg, the
dose was 4 random-donor platelet units/m2.
ABO-compatible leukoreduced red blood cells were
transfused when the hematocrit fell below 20%. If a patient
experienced significant blood loss (≥15% total body vol-
ume), had a preexisting cardiac condition, or developed
symptoms of anemia, then red blood cells were transfused at
the discretion of the attending physician.
Definition of Bleeding Events
Bleeding events were documented daily in the medical
records of each patient by bone marrow transplantation
nurses, physician assistants, fellows, and attending physi-
cians who directly cared for the enrolled patient. A single
dedicated study nurse reviewed the records of each patient
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Top, Platelet transfusion algorithm for patients assigned to receive prophylactic platelet (plt) transfusions at 10,000/µL. Bottom, Platelet transfusion
algorithm for patients assigned to receive prophylactic platelet transfusions at 20,000/µL. CCI indicates corrected count increment. Differences
between the two algorithms are indicated in bold face.
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daily to assign a bleeding score for each event. Bleeding
events were based on the modiﬁed Gruppo Italiano Malattie
Ematologiche Maligne dell’Adulto (GIMEMA) study crite-
ria, as summarized in Table 1 [12]. Petechial, mucosal, and
microscopic bleeding, as well as melena and hematemesis
not requiring red blood cell transfusion, were considered
minor bleeding events. Gross hematuria, any bleeding
requiring red cell transfusion, retinal bleeding, and central
nervous system (CNS) bleeding were considered major
bleeding events. The study, for both practical and safety rea-
sons, was unblinded and each practitioner was aware of the
trigger value for each patient.
Other
Patients received hematopoietic stem cells collected
from either peripheral blood or bone marrow harvest. All
patients received antibiotics and supportive care based on
standardized supportive care guidelines. Prophylactic antibi-
otics were begun on the day of stem cell infusion. Patients
receiving an allogeneic transplant received GVHD prophy-
laxis with methotrexate and cyclosporine or tacrilums.
Myeloid growth factors were administered at the discretion
of the attending physician.
Statistical Methods
We used a dynamic permuted block design for alloca-
tion to treatment arms based on the following stratiﬁcation
factors: type of transplantation (allogeneic, autologous, or
MUD), type of conditioning regimen (± radiation therapy
and ± cyclophosphamide), and age (<13 years versus ≥13
years). We used an intent-to-treat approach.
All statistical analyses were performed using the Statisti-
cal Analysis System (version 8.0; SAS Institute, Cary, NC).
Simple t tests were used to compare independent means for
the continuous outcome variables (eg, number of platelet units
transfused) against dichotomous covariates (eg, treatment-
group assignment). A general linear-model approach was
used for multivariate analyses of platelet use and indepen-
dent variables such as treatment arm assignment, age, trans-
plant type, infection, and amphotericin B use. The χ2 test
was used to assess the association between a categorical out-
come variable such as the development of an incident bleed-
ing complication and a dichotomous covariate such as 10K
versus 20K treatment-group assignment.
Multivariate analyses were performed. For quantitative
outcome variables such as the number of platelet units
transfused, the number of bleeding days, etc, we used gen-
eral linear model analysis and examined the association
between the outcome variable and study covariates (eg, 10K
versus 20K treatment-group assignment). For dichotomous
outcome variables such as incident bleeding complication,
we used unconditional logistic regression analysis to assess
the independent association between the outcome variable
and study covariates. For logistic regression analyses, the
odds ratio (OR) is reported as a summary of the magnitude
of the association between a covariate and the outcome vari-
able. Other covariates included in the multivariate models
were the stratiﬁcation variables (age, conditioning regimen,
and type of transplant).
Initial sample size estimates called for a total accrual of
268 patients to detect a 25% difference in platelet unit trans-
fusions with a power of 80% and an α = 0.05 (2-sided compar-
ison). The accrual target was not reached. We had a total of
159 patients actually accrued onto this protocol. With the
original planning parameters and actual accrual, we could have
detected a 32.5% or greater reduction in total platelet use.
RESULTS
Between July 1997 and December 2000, 159 patients
were enrolled into the study. Seventy-nine patients were ran-
domized to the 10 × 109/L trigger group and 81 to the 20 ×
109/L threshold group. Three patients were lost to follow-up
before day 100 (on days 90, 62, and 72), and these results
were censored. Four patients had early relapse (10K versus
20K, 2 versus 2) or death (10K versus 20K, 8 versus 5). Two
patients had early termination because chemotherapy was to
be administered for second transplantation. Three patients,
all with cytomegalovirus infection, still required treatment
with platelet transfusions at the end of their observation
period. Patient characteristics are shown in Table 2.
For the vast majority (98.4%) of transfusions, single-
donor products were available. Pooled platelets were used in
27 (1.6%) of the 1647 transfusions. Four patients were evalu-
ated for platelet alloimmunization. In 3 patients, an anti-HLA
or antiplatelet antibody was detected. Two HLA-matched
platelet transfusions were given during the study period.
The maximum bleeding score (major, minor, or none),
based on modified GIMEMA criteria, was determined for
each patient (Table 3). Fourteen percent of patients in the 10K
arm compared to 17% in the 20K arm had major bleeding
events. There was no difference between the two arms in max-
imum bleeding scores (P = .66). The causes of bleeding were
similar for the 2 groups (Table 4) and were primarily mucocu-
taneous and genitourinary. Two nonfatal CNS bleeds occurred
in the 10K group and 1 in the 20K group. In 2 of 3 cases (1
10K, 1 20K) the platelet count was above the trigger value
when the CNS event occurred. Eight deaths occurred in the
10K group and 5 in the 20K group (P = .35), none attributable
to bleeding. The mean number of bleeding-days per patient
was similar for the 2 groups (11.4 versus 11.4, P = .99). Most
bleeding-days were due to minor bleeding (10K versus 20K,
10.2 days versus 10.2 days, P = .96), whereas bleeding-days due
to major bleeding were less frequent (10K versus 20K, 1.2
days versus 1.2 days, P = .96). There were no signiﬁcant differ-
ences between the 2 groups in the numbers of minor and
major bleeding-days. Patients undergoing autologous trans-
Table 1. Assigned Bleeding Scores Based on Modiﬁed GIMEMA Criteria
Bleeding Score Bleeding Type
0 None
1 Petechial, mucosal, microscopic
2a Melena or hematemesis not requiring red cell 
transfusion
2b Gross hematuria
3 Bleeding requiring red cell transfusion
4 Retinal bleeding with visual impairment
5 Nonfatal cerebral bleeding
6 Fatal cerebral bleeding
7 Fatal noncerebral bleeding
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plantation experienced 6.1 versus 7.3 days of bleeding (10 ver-
sus 20K, P = .28). For patients receiving allogeneic or MUD
grafts, bleeding was more frequent, but the differences were
not statistically signiﬁcant between the 2 treatment arms (10K
versus 20K: allogeneic 17.8 days versus 17.9 days, P = .98;
MUD 19.9 days versus 15.4 days, P = .44). The time from
transplantation until bleeding was ﬁrst recorded averaged 3.7
days in the 10K arm versus 4.2 days in the 20K arm (P = .51).
The mean number of packed red blood cell transfusions
administered was similar between the 2 groups (6.0 versus 5.9,
P = .93). The median number of inpatient hospital days was
25.6 in the 10K group versus 25.3 (P = .91) in the 20K group.
Univariate analyses of factors associated with major
bleeding are shown in Table 5. The treatment group (10K
versus 20K, P = .66, OR = .79) did not predict bleeding. In
multivariate regression, only amphotericin B use (P = .05; OR
= 2.83) was independently associated with major bleeding.
The total number of platelet transfusions was similar in the
10K and 20K groups (812 versus 830, 10.4/patient versus
10.2/patient, P = .94) (Table 6). The majority of transfusions
were given for prophylactic indications (10K arm, 83%; 20K
arm, 89%). In patients undergoing autologous transplantation,
the number of prophylactic transfusions was low regardless of
trigger value (10K versus 20K, 4.1 versus 5.6, P = .27). Patients
undergoing allogeneic or MUD transplantation received more
prophylactic transfusions (10K versus 20K: allogeneic 11.3 ver-
sus 13.6, P = .6; MUD 21.0 versus 13.1, P = .12), but no statisti-
cally signiﬁcant differences were seen between the 2 groups.
Patients undergoing autologous transplantation required
few transfusions for therapeutic indications (10K versus 20K,
0.09/patient versus 0.33/patient, P = .27). Patients receiving
allogeneic or MUD transplants received more therapeutic
transfusions, but statistically signiﬁcant differences were not
noted between the 2 arms (10K versus 20K: allogeneic 5.0
versus 1.7, P = .28; MUD 2.3 versus 3.9, P = .55).
Univariate analyses of factors associated with platelet
use are shown in Table 5. This result was invariant to adjust-
ment for the other covariates as we assessed the effect of
trigger value on platelet use stratifying for GVHD, VOD,
infection, or amphotericin B use. In no instance was trigger
assignment signiﬁcantly related to platelet use. In a multi-
variate regression analysis using the above covariates, the
use of amphotericin B (P < .0001), presence of GVHD (P <
.049), and presence of VOD (P < .033) all remained signiﬁ-
cant independent predictors, whereas trigger value did not.
A substantial number of prophylactic platelet transfu-
sions were given at platelet levels above the assigned 10K
and 20K values for protocol-specified indications: recent
major bleeding events (80 versus 52 transfusions), recent
minor bleeding events (71 versus 20 transfusions), a planned
procedure (89 versus 57 transfusions), or a change in clinical
condition (64 versus 22 transfusions) in the 10K versus 20K
cohorts. A minority of patients in the 10K arm accounted
Table 2. Characteristics of Patients Randomized to Receive Prophylactic
Platelet Transfusions at Threshold Values of 10,000/µL versus 20,000/µL
Threshold Threshold
10,000/µL 20,000/µL
Total no. randomized 78 81
Gender, no. (%)
Male 44 (56) 39 (48)
Female 34 (44) 42 (52)
Age, median (range), y 44 (8-70) 47 (3-69)
Diagnosis
Leukemia 24 29
Lymphoma 22 22
Myeloma 9 5
Solid tumor/other 23 25
Transplant type, no. (%)
Autologous 45 (58) 46 (57)
Allogeneic 21 (27) 20 (25)
MUD 12 (15) 15 (18)
Entry platelet count, ×109/µL
Mean ± SD 126 ± 96 152 ± 113
Median (range) 97 (16-400) 136 (25-774)
Entry hematocrit, %
Mean ± SD 31 ± 5.1 30 ± 5.2
Median (range) 31 (20-44) 30 (16-44)
CD34+ stem cell dose, ×106/kg
Mean ± SD 4.52 ± 2.2 4.15 ± 2.0
Median (range) 4.09 (.43-10.8) 4.09 (1.19-10.8)
Conditioning regimen, no. (%)
Total body irradiation 18 (25) 19 (23)
Cyclophosphamide 42 (55) 50 (62)
Transplantation complications, 
no. (%)
GVHD 23 (29) 30 (37)
Documented infection 42 (54) 53 (65)
Amphotericin B use 18 (23) 12 (15)
Table 3. Maximum Bleeding Severity for Patients Randomized to Receive
Prophylactic Platelet Transfusions at 10,000/µL or 20,000/µL*
Most Severe Bleeding Threshold Threshold
per Subject 10,000/µL 20,000/µL
No bleeding, no. (%) 4 (5) 2 (2)
Minor bleeding, no. (%) 63 (81) 65 (80)
Major bleeding, no. (%) 11 (14) 14 (17)
*Petechial, mucosal, and microscopic bleeding, as well as mild
melena and hematemesis not requiring red blood cell transfusion were
considered minor bleeding events. Gross hematuria, any bleeding
requiring red cell transfusion, retinal bleeding, and CNS bleeding were
considered major bleeding events.
Table 4. Characteristics of Maximum Bleeding Scores for Patients Random-
ized to Receive Prophylactic Platelet Transfusions at 10,000/µL or 20,000/µL
Type of Bleeding Threshold Threshold
Episode 10,000/µL (n = 78) 20,000/µL (n = 81)
None 4 2
Mucosal* 53 58
Melena* 10 7
Mucosal or melena requiring 1 8 
red blood cell transfusion
Gross hematuria 8 5
Cerebral nonfatal 2 1
Cerebral fatal 0 0
Noncerebral fatal 0 0
*Not requiring red blood cell transfusion.
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for a disproportionate number of transfusions for each of
these indications (4 patients with ≥10 transfusions for a
given indication, totaling 100 transfusions), whereas only
1 patient in the 20K arm received more than 10 transfusions
for any given indication. For investigation of whether there
were differences in transfusion practices between the 2 arms,
several exploratory post-hoc analyses were performed. An
average of 4.27 (10K) versus 1.89 (20K) prophylactic platelet
transfusions per patient (P = .049) were given above the
assigned trigger value. Patients in the 10K arm had their
transfusion trigger raised above the assigned parameter for a
total of 356 days, compared to 184 days in the 20K group.
DISCUSSION
Several prospective studies over the last decade have
sought to determine the lowest yet safest prophylactic
platelet transfusion threshold in patients undergoing treat-
ment for acute leukemia [11-13,15]. These studies have
shown that a trigger threshold of 10K is safe and results in
lower platelet use. Gil-Fernandez and colleagues investi-
gated a stringent platelet transfusion policy in 2 different
cohorts of BMT patients [14]. The first group underwent
transplantation between 1990 and 1992, when the threshold
for prophylactic platelet transfusion was 20 × 109/L. This
group was historically compared to a second cohort of
patients who underwent transplantation between 1993 and
1995 using a platelet transfusion threshold of 10 × 109/L.
However, patients with clinical factors suggestive of “high”
platelet consumption were given a transfusion at a level of
20 × 109/L for as long as the risk factors remained. A 26%
decrease in the number of platelet transfusions administered
was noted with the more stringent strategy. No excess hem-
orrhagic complications were seen.
Our trial also indicates that a prophylactic platelet trans-
fusion threshold of 10 × 109/L can be safely adopted in bone
marrow and peripheral blood stem cell recipients. We used a
modiﬁcation of the GIMEMA system to score bleeding [12].
In our study patients, the incidence of major bleeding (10K
versus 20K, 14% versus 17%) was similar to the incidence
Table 5. Univariate Predictors of Major Bleeding and Platelet Use
Major Bleeding, Univariate Analysis*
Parameter OR (95% Confidence Interval) P
Amphotericin B use 3.8 (1.3-10.5) .01
GVHD (any grade) 3.1 (1.2-8.2) .01
Transplantation type (auto versus allo or MUD) 2.8 (1.1-7.7) .03
VOD (any grade) 4.4 (0.6-27.8) .08
Trigger arm (10,000/µL versus 20,000/µL) 0.8 (0.3-2.0) .66 
Platelet Utilization, Univariate analysis
Parameter Mean ± SD P
GVHD (any grade, yes versus no) 19.3 ± 19.9 versus 5.8 ± 6.9 units <.0001
Transplantation type (auto versus allo or MUD) 5.1 ± 6.0 versus 17.4 ± 18.5 units <.0001
Amphotericin B use (yes versus no) 25.2 ± 22.2 versus 6.9 ± 8.6 units .0001 
VOD (any grade, yes versus no) 26.0 ± 22.0 versus 9.6 ± 13.4 units .10
Trigger arm (10,000/µL versus 20,000/µL) 10.4 ± 17.0 versus 10.2 ± 11.0 units .95 
*Auto indicates autologous; allo, allogeneic.
Table 6. Platelet Transfusion Characteristics of Patients Assigned to Receive Prophylactic or Therapeutic Platelet Transfusions at 10,000/µL versus 20,000/µL
Threshold 10,000/µL Threshold 20,000/µL P
Total no. platelet transfusions 812 830
Mean ± SD per patient 10.4 ± 17 10.2 ± 11 .95
Median (range) 3 (0-97) 5 (1-47)
No. prophylactic* platelet transfusions 674 724
Mean ± SD per patient 8.6 ± 12.5 8.9 ± 8.8 .86
Median (range) 3 (0-63) 5 (0-40)
Auto BMT (mean ± SD per patient) 4.1 ± 5.1 5.6 ± 6 .2
Allo BMT (mean ± SD per patient) 11.3 ± 16.4 13.6 ± 10.6 .6
MUD BMT (mean ± SD per patient) 21.0 ± 15.6 13.1 ± 9.7 .12
No. therapeutic* platelet transfusions 138 106
Mean ± SD per patient 1.8 ± 7.3 1.3 ± 4.2 .63
Median (range) 0 (0-52) 0 (0-27)
Auto BMT (mean ± SD per patient) 0.09 ± 0.36 0.33 ± 1.38 .27
Allo BMT (mean ± SD per patient) 5.0 ± 13.4 1.7 ± 4.1 .28
Mud BMT (mean ± SD per patient) 2.3 ± 4.4 3.9 ± 7.9 .55
*Prophylactic indicates platelet transfusion for reasons other than active bleeding, including recent but not active bleeding episodes; therapeutic
indicates platelet transfusion given for active bleeding episodes.
Prophylactic Platelet Transfusion Threshold in HSCT
575B B & M T
reported in 3 recent prospective studies [11-13,15] in
patients undergoing induction chemotherapy for acute myel-
ogenous leukemia (18% versus 16.6%). CNS hemorrhage
was rare in our study. Three patients in our study experi-
enced CNS bleeds, with only a single patient in the 10K arm
having a platelet count below the trigger value (9 × 109/L) at
the time of bleeding. No deaths attributable to hemorrhage
occurred in our study, a result similar to the low incidence of
1.0% to 1.5% noted in other trigger studies [15]. In prior
studies, the platelet count was often above the prophylactic
platelet trigger value when fatal hemorrhage occurred [11-
13]. Studies by Hanson and Slichter have suggested that in
stable patients only a minimal number of platelets may be
necessary to participate in endothelial repair and maintain
hemostasis [23]. Other investigators have suggested that a
trigger value of 5 × 109/L, which potentially results in no
prophylactic transfusions, may be appropriate in a subset of
low-risk stable patients [6]. In our study, although GVHD,
transplant type, and Amphotericin B use were all predictors
of major bleeding according to univariate analysis results,
only the use of amphotericin B was a signiﬁcant predictor
according to multivariate analysis results. Because major
bleeding was infrequent during the study (1.2 d/patient for
both arms), a greater number of patients may be needed to
determine if there were other signiﬁcant predictors of major
bleeding that we were unable to identify.
Results of studies of patients with acute leukemia have
shown that a 20% to 35% decrease in platelet use occurs with
a 10K trigger; our results, however, did not confirm a
decrease in platelet use when a more stringent platelet trans-
fusion strategy was used. Several explanations may account
for these ﬁndings.
BMT patients experience many complications resulting
in increased platelet use and refractoriness. Because of
greater intensity of the cytotoxic conditioning regimen, tox-
icities that lead to a greater propensity for hemorrhage are
more frequent after BMT than after acute leukemia treat-
ment regimens. In our study, as in previous studies in acute
leukemia, protocol-speciﬁed safety measures were incorpo-
rated for prophylactic transfusions at higher platelet levels
to minimize risk for hemorrhage. In earlier studies these
factors included active bleeding, planned procedures, fever,
coagulation deficiencies, sepsis, VOD, mucositis, and
amphotericin B administration [11-14]. In a trigger study
performed by Rebulla et al. [13], such safety measures led to
a substantial number of transfusions given above the
assigned trigger threshold in the 10K arm (28%, 5% of
which were considered protocol violations) compared to the
20K arm (2% protocol violations). In our study, we used
active or recent minor or major bleeding, planned proce-
dures, or a worsening of the clinical condition as indications
for administering transfusions above the assigned trigger
threshold. This protocol led to a substantial number of our
patients receiving transfusions over their predetermined
trigger values. Forty-nine percent of the transfusions in the
10K arm, compared to 21% of transfusions in the 20K arm,
were given above the assigned prophylactic threshold values.
It is possible that in our unblinded study, as with earlier
studies, clinicians may have been more reluctant to quickly
return to the 10K trigger value in patients with persisting
safety concerns. This possibility is supported by the fact that
patients in the 10K arm were maintained at triggers above
their assigned threshold for a greater number of total days
than were patients in the 20 K arm (356 versus 184 days,
respectively). In addition, in the 10K arm a minority of
patients received a disproportionate number of transfusions
above the threshold; 4 patients received 100 transfusions.
Indications for these transfusions included prophylaxis dur-
ing daily electroconvulsive therapy in a patient with debili-
tating depression (22 transfusions), prophylaxis after splenic
rupture (33 transfusions), and prophylaxis after minor and
major bleeding events (45 transfusions). In the 20K group, a
single patient received more than 10 transfusions over the
threshold value; 21 transfusions for prophylaxis after a gas-
trointestinal hemorrhage.
Safety considerations likely contributed to the lack of
difference in platelet use in our study. Whether or not such
safety considerations are necessary is not known. Two other
factors also contributed to the lack of difference in platelet
use. First, a subtle imbalance in our randomization may have
existed. A trend was noted toward more amphotericin B use
in the 10 K arm than in the 20K arm (23% versus 15%, P =
.18). In multivariate analysis, amphotericin B use was noted
to be the strongest independent predictor of platelet con-
sumption. This trend may have further obscured a differ-
ence in platelet use.
Another possible reason for the lack of difference in
platelet use in our study was that patients in the 10K arm, as
opposed to those in the 20K trigger arm, had evening
platelet counts monitored if their morning values were
between 10 to 15 × 109/L. The rationale for this additional
safety feature was that a previous study had shown that
platelets are consumed at an average rate of 740 µL/hr in
patients without platelet transfusion refractoriness [24]. It
was therefore likely that many patients with morning
platelet counts less than 15 × 109/L would have a platelet
count less than 10 × 109/L later that evening. In the 10K
arm, 188 platelet counts were checked for this reason.
Eighty-six (46%) of these 188 patients were given a prophy-
lactic platelet transfusion that evening because their platelet
count had dropped below the 10 × 109/L threshold. These
86 transfusions represented 11% (86/812) of the total num-
ber of transfusions in the 10K arm. However, only 13 of the
86 patients who required these evening transfusions needed
another transfusion the next morning. Thus, less than 2% of
the total number of transfusions were prompted by this
safety measure.
In the 30 months of our trial we accrued 159 patients.
The trial was closed before our accrual target of 268 patients
was reached because the referral pattern for our BMT unit
had signiﬁcantly changed. Fewer autologous transplantations
were being performed for breast cancer, and a larger number
of nonmyeloablative transplantations were being considered,
which were not included in our original study design.
Because of these changes in referral and the anticipated slow
accrual, we decided to close the protocol in December 1999.
Thus we had only sufﬁcient power to detect a 32.5% reduc-
tion in the total use of platelet units. With a much larger
sample size, smaller differences in platelet use may have
become evident.
In summary, we have shown that a more stringent
platelet transfusion strategy is safe and does not result in
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excess bleeding. Platelet use was not decreased in our study,
but savings in platelet use may have been masked by safety
measures within our study design. Whether or not these
additional safety measures as written into our protocol were
needed and whether elimination of such commonly used
safety provisions would reduce the transfusion requirement
are unknown. Alternatively, it is possible that BMT patients
may have a larger complement of adverse predictors of
increased platelet use than do acute leukemia patients, and
these predictors might result in similar transfusion needs in
BMT patients no matter which trigger is chosen. In our
study, for example, multivariate analysis results indicated
that the presence of GVHD, VOD, and amphotericin B use
were all significant predictors of platelet use, possibly
because of increased platelet consumption or transfusion
refractoriness in the presence of these conditions.
Because periods of cytopenia are shorter with peripheral
blood stem cell transplantation, which has become the pre-
ferred source for hematopoietic reconstitution, demonstra-
tion of differences in clinical or financial impact resulting
from the use of the 2 trigger values may become more difﬁ-
cult and require larger clinical trials. Thus, it remains to be
proven whether a more restrictive platelet transfusion strat-
egy will lead to decreased platelet use in a BMT population.
We believe these data indicate that the use of a 10K platelet
transfusion threshold is a reasonable and safe option.
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